US military awards MediVector $138M for a much-needed, broad-spectrum flu therapeutic
This article was originally published in Scrip
Executive Summary
The Boston-based drug development firm, MediVector, has won a $138.5 million contract under the US Department of Defense’s Joint Project Manager Transformational Medical Technologies (JPM-TMT) initiative to further develop a broad-spectrum therapeutic against multiple influenza viruses, the oral drug favipiravir (T-705). It has been called a novel antiviral.